CorMatrix Cardiovascular said it received FDA 510(k) clearance for its Cor Patch epicardial patch.
The Cor Patch epicardial patch is designed to repair the atria and the left and right ventricular walls of the heart that are thin or damaged as a result of myocardial infarct.
“We have a unique opportunity to enhance the repair and recovery of heart muscle after injury using the Cor Patch technology. This could be a game changer for patients undergoing surgical procedures aimed to increase the blood supply to damaged areas of their heart. My translational research provides an important foundation of data to support the clinical use of this technology as an epicardial patch during coronary bypass surgery. We can now directly target damaged muscle in addition to bypassing blocked vessels,” Dr. Paul Fedak, professor of cardiac surgery at the Cumming School of Medicine at the University of Calgary, said in a press release.
CorMatrix Cardiovascular says on its website that the patch minimizes inflammatory reactions after implantation and has the structural support needed for epicardial structures. It comes in a pack of 5 with 5cm x 5cm and 7cm x 10cm sizes.
“The ECM technology and our knowledge of the underlying physiological mechanisms for regeneration continues to rapidly grow. The Cor Patch represents our entry into epicardial tissue repair and support. Our pipeline is becoming full of some very compelling products,” chief medical & scientific officer Robert Matheny said.
“The Cor Patch is the first next-generation ECM product cleared by the FDA for epicardial tissue support and repair. The introduction of the Cor Patch epicardial patch to the cardiac surgery market represents the first of a rapidly developing CorMatrix pipeline of next-generation ECM products and patient solutions,” added president and CEO Edgar Rey.
